A recently developed, experimental drug has demonstrated significant potential in extending the lives of pancreatic cancer patients, according to the latest clinical results. Initial market availability is anticipated first in the United States, with subsequent rollout planned for European nations. However, questions remain regarding the accessibility of this promising therapy for patients in Kosovo.
Oncologist Ilir Kurtishi addressed this topic during an appearance on the “Health First” podcast, supported by United Hospital. He indicated that while the medication offers substantial benefits, access for Kosovo and other Balkan or European countries is contingent upon the completion of necessary international and local procedural benchmarks. Kurtishi specified that for the region to benefit from the new treatment, several regulatory hurdles must be cleared.
These procedures include achieving formal certification that aligns with established European standards, alongside securing approval from the European Medicines Agency (EMA). This suggests that while the drug represents a major medical advancement, the integration of this novel therapy into the healthcare system of Kosovo, and similar nations, will require adherence to rigorous international protocols before patients can receive it.
Topics: #patients #kosovo #new
Oncologist Ilir Kurtishi spoke regarding the potential availability of a new experimental drug for pancreatic cancer. According to the latest clinical results, the drug has demonstrated significant po
What is the expected timeline for the drug’s availability in Kosovo?